Clinical Trial Update: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab as first-line therapy in chronic lymphocytic leukemia/small lymphocytic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Chlorambucil (chlorambucil)
• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-03-28